StatOrigin open statistical archive
Live Industries Statistics Regions Rankings Reports Compare Sources

ISIC Q86 · Industry hub · 7 publishers

Healthcare statistics

79,502 verified figures across 96 measures of the healthcare industry, from 7 publishers in 213 regions. Every number opens the report and sentence it was taken from.

CSV JSON Cite and reuse

79,502 verified figures Updated 4 Oct 2026 Reviewed 17 Sep 2026 Sources typically refresh annually

Key findings

The most quotable figures in this dataset, each with its publisher. Copy a citation or open the record to read the source sentence.

Market size and output 4

  1. Medicine spending worldwide was 1.6 trillion USD in 2023 (IQVIA). IQVIA ↗
  2. Cell and gene therapy spending worldwide was 5.9 billion USD in 2023 (IQVIA). IQVIA ↗
  3. Multi-country oncology trial starts worldwide were 403 in 2024 (IQVIA). IQVIA ↗
  4. Oncology clinical trial starts worldwide were 2,162 in 2024 (IQVIA). IQVIA ↗

Growth and change 1

  1. Cell and gene therapy spending growth rate worldwide was 38% in 2023 (IQVIA). IQVIA ↗

Prices and costs 2

  1. Oncology medicine spending at list prices worldwide was 252 billion USD in 2024 (IQVIA). IQVIA ↗
  2. IQVIA projects oncology medicine spending at list prices worldwide at 441 billion USD in 2029. IQVIA ↗

Adoption and share 1

  1. Global Initiative for Childhood Cancer country coverage was 90 between 1 January 2018 and 15 September 2026 (WHO). WHO ↗ T1 Official

Other measures 6

  1. Global Platform participating governments were 12 (WHO, published 15 September 2026). WHO ↗ T1 Official
  2. Global Platform participating countries were 12 between 1 January 2024 and 15 September 2026 (WHO). WHO ↗ T1 Official
  3. Market shaping strategy interventions worldwide were 10 (WHO, published 15 September 2026). WHO ↗ T1 Official
  4. Cell and gene therapy venture capital and public funding deal value worldwide was 3.4 billion USD in 2023 (IQVIA). IQVIA ↗
  5. Novel active substance launches worldwide were 79 in 2025 (IQVIA). IQVIA ↗
  6. Global Initiative for Childhood Cancer beneficiaries was nearly 500,000 between 1 January 2018 and 15 September 2026 (WHO). WHO ↗ T1 Official

Charts

The best-covered series in this dataset. Every chart can be embedded with its attribution line, and its underlying data is one click below it.

Life expectancy at birth, total (years)

Monaco, 1960 to 2024

65 observations · 1960 to 2024

Estimates are listed as such in the table below

Life expectancy at birth, total (years)Life expectancy at birth, total (years). 65 observations from 1960 to 2024, ranging from 71.9 years to 86.5 years. Latest value 86.5 years (2024). years 0 20 40 60 80 100 1960 1971 1982 1993 2004 2015 86.5
Life expectancy at birth, total (years)Life expectancy at birth, total (years). 65 observations from 1960 to 2024, ranging from 71.9 years to 86.5 years. Latest value 86.5 years (2024). years 0 30 60 90 1960 1971 1982 1993 2004 2015 86.5
Life expectancy at birth, total (years)Life expectancy at birth, total (years). 65 observations from 1960 to 2024, ranging from 71.9 years to 86.5 years. Latest value 86.5 years (2024). years 0 30 60 90 1960 1971 1982 1993 2004 2015 86.5
View the underlying data
Life expectancy at birth, total (years)
Period Type Value
1960 Estimate 71.9 years
1961 Estimate 72.2 years
1962 Estimate 72.4 years
1963 Estimate 72.5 years
1964 Estimate 72.7 years
1965 Estimate 72.9 years
1966 Estimate 73 years
1967 Estimate 73.1 years
1968 Estimate 73.2 years
1969 Estimate 73.2 years
1970 Estimate 73.3 years
1971 Estimate 73.4 years
1972 Estimate 73.4 years
1973 Estimate 73.4 years
1974 Estimate 73.4 years
1975 Estimate 73.5 years
1976 Estimate 73.8 years
1977 Estimate 74.2 years
1978 Estimate 74.7 years
1979 Estimate 74.9 years
1980 Estimate 74.9 years
1981 Estimate 75 years
1982 Estimate 75.3 years
1983 Estimate 75.7 years
1984 Estimate 76.4 years
1985 Estimate 77.4 years
1986 Estimate 78.4 years
1987 Estimate 79.3 years
1988 Estimate 79.4 years
1989 Estimate 79.4 years
1990 Estimate 79.4 years
1991 Estimate 79.7 years
1992 Estimate 80.1 years
1993 Estimate 80.4 years
1994 Estimate 80.7 years
1995 Estimate 80.9 years
1996 Estimate 81.1 years
1997 Estimate 81.4 years
1998 Estimate 81.6 years
1999 Estimate 81.8 years
2000 Estimate 82.1 years
2001 Estimate 82.5 years
2002 Estimate 83.1 years
2003 Estimate 83.6 years
2004 Estimate 84.2 years
2005 Estimate 84.3 years
2006 Estimate 84.2 years
2007 Estimate 83.9 years
2008 Estimate 83.8 years
2009 Estimate 84.2 years
2010 Estimate 84.6 years
2011 Estimate 85 years
2012 Estimate 85 years
2013 Estimate 85.1 years
2014 Estimate 85.1 years
2015 Estimate 85.3 years
2016 Estimate 85.6 years
2017 Estimate 85.9 years
2018 Estimate 86.1 years
2019 Estimate 86.2 years
2020 Estimate 86.1 years
2021 Estimate 85.1 years
2022 Estimate 85.7 years
2023 Estimate 86.4 years
2024 Estimate 86.5 years
Source: World Bank · years · CC BY 4.0 · statorigin.org
Embed

Free to embed, including commercially. The attribution bar is part of the chart; it is what keeps the data citable. The link under the frame is optional: keep it, remove it or mark it rel="nofollow". 

<iframe src="https://statorigin.org/embed/healthcare--life-expectancy-at-birth-total--trend" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Life expectancy at birth, total (years)" loading="lazy"></iframe>
<p><a href="https://statorigin.org/industries/healthcare">Data: World Bank via StatOrigin</a> · CC BY 4.0</p>
Preview embed

Adult obesity prevalence (age-standardized, %) by country

2024 · 10 countries

Estimate

Adult obesity prevalence (age-standardized, %) by countryAdult obesity prevalence (age-standardized, %) by country. 10 categories, highest is Tonga at 73.8%. Egypt Kiribati Saint Kitts and Nevis Bahamas Micronesia French Polynesia Samoa Tuvalu Nauru Tonga 43.9% 45.6% 46.7% 48.3% 48.6% 49.2% 64.3% 65.1% 71.4% 73.8%
Adult obesity prevalence (age-standardized, %) by countryAdult obesity prevalence (age-standardized, %) by country. 10 categories, highest is Tonga at 73.8%. Egypt Kiribati Saint Kitts and Nevis Bahamas Micronesia French Polynesia Samoa Tuvalu Nauru Tonga 43.9% 45.6% 46.7% 48.3% 48.6% 49.2% 64.3% 65.1% 71.4% 73.8%
Adult obesity prevalence (age-standardized, %) by countryAdult obesity prevalence (age-standardized, %) by country. 10 categories, highest is Tonga at 73.8%. Egypt Kiribati Saint Kitts and Nevis Bahamas Micronesia French Polynesia Samoa Tuvalu Nauru Tonga 43.9% 45.6% 46.7% 48.3% 48.6% 49.2% 64.3% 65.1% 71.4% 73.8%
View the underlying data
Adult obesity prevalence (age-standardized, %) by country
Category Source Type Value
Tonga WHO Estimate 73.8%
Nauru WHO Estimate 71.4%
Tuvalu WHO Estimate 65.1%
Samoa WHO Estimate 64.3%
French Polynesia WHO Estimate 49.2%
Micronesia WHO Estimate 48.6%
Bahamas WHO Estimate 48.3%
Saint Kitts and Nevis WHO Estimate 46.7%
Kiribati WHO Estimate 45.6%
Egypt WHO Estimate 43.9%
Source: WHO · percent · CC BY 4.0 · statorigin.org
Embed

Free to embed, including commercially. The attribution bar is part of the chart; it is what keeps the data citable. The link under the frame is optional: keep it, remove it or mark it rel="nofollow". 

<iframe src="https://statorigin.org/embed/healthcare--adult-obesity-prevalence-total--by-country" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Adult obesity prevalence (age-standardized, %) by country" loading="lazy"></iframe>
<p><a href="https://statorigin.org/industries/healthcare">Data: WHO via StatOrigin</a> · CC BY 4.0</p>
Preview embed

Adult obesity prevalence: female (age-standardized, %) by country

2024 · 10 countries

Estimate

Adult obesity prevalence: female (age-standardized, %) by countryAdult obesity prevalence: female (age-standardized, %) by country. 10 categories, highest is Tonga at 81.4%. Kiribati Belize Saint Kitts and Nevis Micronesia Bahamas Egypt Nauru Tuvalu Samoa Tonga 52.9% 53.5% 55.3% 57% 57% 57.1% 71.4% 72.3% 76.4% 81.4%
Adult obesity prevalence: female (age-standardized, %) by countryAdult obesity prevalence: female (age-standardized, %) by country. 10 categories, highest is Tonga at 81.4%. Kiribati Belize Saint Kitts and Nevis Micronesia Bahamas Egypt Nauru Tuvalu Samoa Tonga 52.9% 53.5% 55.3% 57% 57% 57.1% 71.4% 72.3% 76.4% 81.4%
Adult obesity prevalence: female (age-standardized, %) by countryAdult obesity prevalence: female (age-standardized, %) by country. 10 categories, highest is Tonga at 81.4%. Kiribati Belize Saint Kitts and Nevis Micronesia Bahamas Egypt Nauru Tuvalu Samoa Tonga 52.9% 53.5% 55.3% 57% 57% 57.1% 71.4% 72.3% 76.4% 81.4%
View the underlying data
Adult obesity prevalence: female (age-standardized, %) by country
Category Source Type Value
Tonga WHO Estimate 81.4%
Samoa WHO Estimate 76.4%
Tuvalu WHO Estimate 72.3%
Nauru WHO Estimate 71.4%
Egypt WHO Estimate 57.1%
Bahamas WHO Estimate 57%
Micronesia WHO Estimate 57%
Saint Kitts and Nevis WHO Estimate 55.3%
Belize WHO Estimate 53.5%
Kiribati WHO Estimate 52.9%
Source: WHO · percent · CC BY 4.0 · statorigin.org
Embed

Free to embed, including commercially. The attribution bar is part of the chart; it is what keeps the data citable. The link under the frame is optional: keep it, remove it or mark it rel="nofollow". 

<iframe src="https://statorigin.org/embed/healthcare--adult-obesity-prevalence-female--by-country" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Adult obesity prevalence: female (age-standardized, %) by country" loading="lazy"></iframe>
<p><a href="https://statorigin.org/industries/healthcare">Data: WHO via StatOrigin</a> · CC BY 4.0</p>
Preview embed

Adult obesity prevalence: male (age-standardized, %)

Nauru, 1990 to 2024

35 observations · 1990 to 2024

Estimates are listed as such in the table below

Adult obesity prevalence: male (age-standardized, %)Adult obesity prevalence: male (age-standardized, %). 35 observations from 1990 to 2024, ranging from 64.4% to 71.4%. Latest value 71.4% (2024). % 0 20 40 60 80 1990 1996 2002 2008 2014 2020 71%
Adult obesity prevalence: male (age-standardized, %)Adult obesity prevalence: male (age-standardized, %). 35 observations from 1990 to 2024, ranging from 64.4% to 71.4%. Latest value 71.4% (2024). % 0 20 40 60 80 1990 1996 2002 2008 2014 2020 71%
Adult obesity prevalence: male (age-standardized, %)Adult obesity prevalence: male (age-standardized, %). 35 observations from 1990 to 2024, ranging from 64.4% to 71.4%. Latest value 71.4% (2024). % 0 20 40 60 80 1990 1996 2002 2008 2014 2020 71%
View the underlying data
Adult obesity prevalence: male (age-standardized, %)
Period Type Value
1990 Estimate 65.5%
1991 Estimate 65.6%
1992 Estimate 65.6%
1993 Estimate 65.6%
1994 Estimate 65.6%
1995 Estimate 65.5%
1996 Estimate 65.3%
1997 Estimate 65.2%
1998 Estimate 65%
1999 Estimate 64.9%
2000 Estimate 64.7%
2001 Estimate 64.6%
2002 Estimate 64.5%
2003 Estimate 64.4%
2004 Estimate 64.4%
2005 Estimate 64.5%
2006 Estimate 64.6%
2007 Estimate 64.8%
2008 Estimate 65%
2009 Estimate 65.3%
2010 Estimate 65.6%
2011 Estimate 66%
2012 Estimate 66.3%
2013 Estimate 66.7%
2014 Estimate 67.1%
2015 Estimate 67.5%
2016 Estimate 67.9%
2017 Estimate 68.3%
2018 Estimate 68.7%
2019 Estimate 69.1%
2020 Estimate 69.6%
2021 Estimate 70%
2022 Estimate 70.5%
2023 Estimate 70.9%
2024 Estimate 71.4%
Source: WHO · percent · CC BY 4.0 · statorigin.org
Embed

Free to embed, including commercially. The attribution bar is part of the chart; it is what keeps the data citable. The link under the frame is optional: keep it, remove it or mark it rel="nofollow". 

<iframe src="https://statorigin.org/embed/healthcare--adult-obesity-prevalence-male--trend" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Adult obesity prevalence: male (age-standardized, %)" loading="lazy"></iframe>
<p><a href="https://statorigin.org/industries/healthcare">Data: WHO via StatOrigin</a> · CC BY 4.0</p>
Preview embed

Healthcare statistics by topic

Each topic gathers one measure across every country and year, with its own country pages and rankings.

Every measure in this dataset

Latest value for each measure, the change from the previous period, and its trend. The full records, with provenance columns, are in the CSV download.

Clinical trial starts 12

Total number of clinical trials initiated during a given period. 12 slices on this page.

Multi-country oncology trial starts Global · 2024 403 −37% since 2021 IQVIA 3 records
Cell and gene therapy clinical trial starts Global · 2023 631 IQVIA 2 records
Large company small molecule share of Phase I clinical trial starts Global · 2025 66% +5 pp since 2022 IQVIA 2 records
Multi-country oncology trial share Global · 2024 20% −17 pp since 2015 IQVIA 2 records
Novel modality share of oncology trials Global · 2024 35% IQVIA 1 record
Oncology clinical trial starts Global · 2024 2,162 IQVIA 1 record
Oncology share of all clinical trials Global · 2024 41% IQVIA 1 record
Phase I share of oncology trials Global · 2024 38% IQVIA 1 record
Show 4 more measures

Medicine spending 11

Total expenditure on pharmaceutical products and therapies. 11 slices on this page.

Oncology medicine spending at list prices Global · 2024 252 billion USD IQVIA 2 records
Cell and gene therapy share of medicine spending Global · 2023 0.4% IQVIA 1 record
Cell and gene therapy spending Global · 2023 5.9 billion USD IQVIA 1 record
Medicine spending Global · 2023 1.6 trillion USD IQVIA 1 record
Share of Pharmerging market pharmaceutical spending growth from top eight countries Global · 2026–2030 Forecast 83% IQVIA 1 record
Net medicine spending growth rate United States · 2025 10.6% IQVIA 2 records
Cell and gene therapy spending average annual growth rate Global · 2019–2023 65% IQVIA 1 record
Cell and gene therapy spending growth rate Global · 2023 38% IQVIA 1 record
Show 3 more measures

Medicine use 8

Total volume or quantity of medicines utilized by a population. 8 slices on this page.

Medicine use index (2020=100) China · 2020 100 index IQVIA 1 record
Non-retail share of medicine use United States · 2025 16% IQVIA 1 record
Retail share of medicine use United States · 2025 84% IQVIA 1 record
Per capita medicine use compound annual growth rate Global · 2026–2030 Forecast 1.9% IQVIA 2 records
Five-year cumulative medicine use growth United States · 2020–2025 13% IQVIA 1 record
Medicine use compound annual growth rate Global · 2026–2030 Forecast 2.7% IQVIA 1 record
Prescription medicine use growth United States · 2025 1.5% IQVIA 1 record
Prescription medicine use growth (5-year) United States · 2021–2025 13% IQVIA 1 record

Novel active substance launches 7

Total number of novel active substances launched on the market. 7 slices on this page.

Oncology novel active substance (NAS) launches (cumulative) Global · 2020–2024 132 +67% since 2015–2019 IQVIA 6 records
Novel active substance launches Global · 2025 79 IQVIA 4 records
Oncology novel active substance (NAS) launches (annual) Global · 2024 25 IQVIA 3 records
Novel active substance launches, five-year total Global · 2021–2025 388 IQVIA 2 records
Domestic-only oncology NAS launches (cumulative) China · 2020–2024 45 IQVIA 1 record
Novel active substance launches, five-year total (excluding COVID-19 products) Global · 2021–2025 369 IQVIA 1 record
Novel active substances launched exclusively in China China · 2025 30 IQVIA 1 record

Healthcare expenditure 6

Total final consumption expenditure on healthcare goods and services. 6 slices on this page.

Current health expenditure (CHE) as percentage of GDP (%) Albania · 2023 7.05% −0.5 pp since 2022 WHO 4540 records
Domestic general government health expenditure as percentage of GDP (%) Albania · 2023 3.5% −0.2 pp since 2022 WHO 4540 records
Healthcare expenditure as share of GDP United Kingdom · 2023 Estimate 10.9% −0.2 pp since 2022 ONS 2 records
Healthcare expenditure United Kingdom · 2023 Estimate 292 billion GBP ONS 1 record
Healthcare expenditure growth, nominal United Kingdom · 2023 Estimate 5.6% ONS 1 record
Healthcare expenditure growth, real United Kingdom · 2023 Estimate -1.4% ONS 1 record

Patient out-of-pocket costs 5

Direct healthcare expenditures paid by patients that are not reimbursed by insurance. 5 slices on this page.

Commercial insurance share of patient out-of-pocket costs United States · 2025 52% IQVIA 1 record
Commercial insurance out-of-pocket cost growth United States · 2025 5% IQVIA 1 record
Commercial insurance out-of-pocket cost growth (5-year) United States · 2020–2025 37% IQVIA 1 record
Medicare out-of-pocket cost decline rate United States · 2025 2.2% IQVIA 1 record
Medicare out-of-pocket cost increase rate versus 2020 United States · 2020–2025 23% IQVIA 1 record

Obesity prevalence 3

The percentage of a population classified as obese, typically defined as having a body mass index (BMI) of 30 kg/m² or higher. 3 slices on this page.

Adult obesity prevalence (age-standardized, %) Afghanistan · 2024 Estimate 20.6% +1 pp since 2023 WHO 6825 records
Adult obesity prevalence: female (age-standardized, %) Afghanistan · 2024 Estimate 26.2% +1.3 pp since 2023 WHO 6825 records
Adult obesity prevalence: male (age-standardized, %) Afghanistan · 2024 Estimate 14.6% +0.6 pp since 2023 WHO 6825 records

Patient organizations 3

Total count of active patient advocacy and support organizations. 3 slices on this page.

Patient organizations focused on rare diseases United States · as of 5 Oct 2023 Estimate 593 IQVIA 1 record
Patient organizations operating United States · as of 5 Oct 2023 3,327 IQVIA 1 record
Share of patient organizations focused on rare diseases United States · as of 5 Oct 2023 Estimate 18% IQVIA 1 record

Tobacco use prevalence 3

The percentage of a population (aged 15 and older) currently using any tobacco product on a daily or non-daily basis. 3 slices on this page.

Tobacco use prevalence (ages 15+, age-standardized, %) Afghanistan · 2024 Estimate 22.1% −0.3 pp since 2023 WHO 1494 records
Tobacco use prevalence: female (ages 15+, age-standardized, %) Afghanistan · 2024 Estimate 6.3% −0.2 pp since 2023 WHO 1494 records
Tobacco use prevalence: male (ages 15+, age-standardized, %) Afghanistan · 2024 Estimate 37.9% −0.5 pp since 2023 WHO 1494 records

Vaccination coverage 3

Percentage of a target population that has received designated vaccines. 3 slices on this page.

DTP3 immunization coverage among 1-year-olds (%) Afghanistan · 2025 Estimate 61% −2 pp since 2024 WHO 4999 records
Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%) Afghanistan · 2025 Estimate 56% −3 pp since 2024 WHO 4999 records
Measles-containing-vaccine second-dose (MCV2) immunization coverage (%) Afghanistan · 2025 Estimate 42% −2 pp since 2024 WHO 4999 records

Countries of operation 2

Total number of countries in which an enterprise conducts business operations or commercial distribution. 2 slices on this page.

Global Initiative for Childhood Cancer country coverage Global · 1 Jan 2018 to 15 Sep 2026 90 WHO 1 record
Global Platform participating countries Global · 1 Jan 2024 to 15 Sep 2026 12 WHO 1 record

Drug overdose deaths 2

Total number of deaths caused by drug overdoses. 2 slices on this page.

Drug overdose deaths United States · 2025–2026 Estimate 67,798 CDC 1 record
Drug overdose deaths year-over-year change United States · 2025–2026 Estimate -12.3% CDC 1 record

Operating locations 2

Total number of distinct operational facilities or sites maintained by an enterprise. 2 slices on this page.

WHO operational locations Global · as of 14 Sep 2026 150 WHO 1 record
WHO presence locations Global · as of 15 Sep 2026 150 WHO 1 record

Patient satisfaction rate 2

Share of patients reporting satisfaction with care received during a healthcare appointment. 2 slices on this page.

NHS dental appointment satisfaction rate United Kingdom · 21 Jul 2026 to 12 Aug 2026 89.9% ONS 1 record
Private dental appointment satisfaction rate United Kingdom · 21 Jul 2026 to 12 Aug 2026 93.5% ONS 1 record

Revenue 2

Total monetary income earned from business operations and sales of goods or services. 2 slices on this page.

Average annual revenue of patient organizations United States · 2016–2020 12.5 billion USD IQVIA 1 record
Annual revenue growth rate of largest patient organizations United States · 2016–2020 5% IQVIA 1 record

Measures with one series 25

One slice each, so they have nothing to add up with on this page.

Life expectancy at birth, total (years) Afghanistan · 2024 Estimate 66.3 years +0.4% since 2023 World Bank 13616 records
Current health expenditure (CHE) per capita (US$) Albania · 2023 590.6 USD +17% since 2022 WHO 4537 records
NCD mortality rate (per 100,000 population) Afghanistan · 2021 Estimate 846.9 per 100,000 people WHO 4070 records
Premature NCD mortality probability (ages 30–70, %) Afghanistan · 2021 Estimate 32.7% −2.1 pp since 2020 WHO 4070 records
Suicide mortality rate (per 100,000 population) Afghanistan · 2021 Estimate 5.32 per 100,000 people WHO 4070 records
Cell and gene therapy venture capital and public funding deal count Global · 2023 96 −1% since 2022 IQVIA 3 records
Change in regional share of global clinical trial country uses European Union · 2019–2025 -17% IQVIA 3 records
AMR-driven annual global GDP reduction Global · 2050 Forecast 3.8% World Bank 1 record
Show 17 more measures

96 measures. Each name opens the full series; each value opens the record with its source evidence.

Answered from the data

Common questions

How big is the global healthcare market?

Medicine spending worldwide was 1.6 trillion USD in 2023 (IQVIA).

Open the full record 1.6 trillion USD 2023 IQVIA

How fast is the healthcare market growing?

Cell and gene therapy spending growth rate worldwide was 38% in 2023 (IQVIA).

Open the full record 38% 2023 IQVIA

Where does this healthcare data come from?

Every figure on this page traces to a primary source: 7 organisations publish the underlying data, and the observed figures span 1960 to 2026, with projections to 2050. The full source table lists each report, its publication date and the original link.

How often is this page updated?

The dataset was last verified on 4 October 2026. Annual series are refreshed when the publisher releases a new edition; corrections are accepted at any time and answered within 48 hours.

Which countries have the most healthcare data?

210 countries have at least one healthcare figure on this page. The best covered are the United States (444 records), China (422) and the United Kingdom (420).

Which healthcare measures have the longest record here?

The page tracks 96 measures. The most complete series are life expectancy at birth, total (years) (13616 records), adult obesity prevalence (age-standardized, %) (6825 records), adult obesity prevalence: female (age-standardized and %) (6825 records).

Sources

Every document behind this page, with the date we read it and whether the link still resolves. All 79502 collected records are published as verified.

36 primary source documents. Every figure on this page traces to one of these.
Document Publisher Authority tier Accessed Locator Data points
CDC Launches New Overdose Prevention Data Channel Press release CDC T1 Official 16 Sep 2026 RELEASE 2
Twenty-Five Years After 9/11 Press release CDC T1 Official 16 Sep 2026 WTC Health Program lung cancer screening findings 1
Data Press release CMS T1 Official 16 Sep 2026 Medicare provider utilization & payment data: Inpatient Hospital Public Use File (PUF) 2
Newsroom Articles Press release CMS T1 Official 16 Sep 2026 Trump Administration Announces $104 Million to Transform Rural Healthcare Across Mississippi Through Cutting-Edge Technology and Expanded Care Closer to Home 1
National Economy Remained Steady with Innovation-Led and High-Quality Development in August Press release NBS China T1 Official 15 Sep 2026 7. Consumer Price Rose Mildly and Producer Prices for Industrial Products Grew Faster Year on Year. 1
Industrial Producer Price Indexes in August 2026 Press release NBS China T1 Official 15 Sep 2026 Table: Industrial Producer Price Indexes in August 2026 — III. Producer Price Indexes for Major Industries (Growth Rate M/M column) 1
Investment in Fixed Assets from January to July 2026 Press release NBS China T1 Official 15 Sep 2026 Table: Investment in Fixed Assets (Excluding Rural Households) from January to July 2026 1
Health care system Press release ONS T1 Official 16 Sep 2026 Spotlight: Healthcare expenditure, UK Health Accounts: 2022 and 2023; Experiences of NHS healthcare services in England: September 2026 7
Health Emergencies Press release World Bank T1 Official 16 Sep 2026 Context 1
World Bank life expectancy at birth (total, years) Dataset World Bank T1 Official 3 Oct 2026 SP.DYN.LE00.IN: {"countryiso3code":"AFG","date":"2024","indicator.id":"SP.DYN.LE00.IN"}; SP.DYN.LE00.IN: {"countryiso3code":"AFG","date":"2023","indicator.id":"SP.DYN.LE00.IN"}; SP.DYN.LE00.IN: {"countryiso3code":"AFG","date":"2022","indicator.id":"SP.DYN.LE00.IN"} 13616
WHO adult obesity prevalence (age-standardized, both sexes) Dataset WHO T1 Official 2 Oct 2026 NCD_BMI_30A: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2024"}; NCD_BMI_30A: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"}; NCD_BMI_30A: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2022"} 6825
WHO adult obesity prevalence (age-standardized, female) Dataset WHO T1 Official 2 Oct 2026 NCD_BMI_30A: {"Dim1":"SEX_FMLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2024"}; NCD_BMI_30A: {"Dim1":"SEX_FMLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"}; NCD_BMI_30A: {"Dim1":"SEX_FMLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2022"} 6825
WHO adult obesity prevalence (age-standardized, male) Dataset WHO T1 Official 2 Oct 2026 NCD_BMI_30A: {"Dim1":"SEX_MLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2024"}; NCD_BMI_30A: {"Dim1":"SEX_MLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"}; NCD_BMI_30A: {"Dim1":"SEX_MLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2022"} 6825
WHO advances access to quality-assured, child-friendly cancer medicines Press release WHO T1 Official 16 Sep 2026 From identifying needs to stimulating product development 1
WHO current health expenditure (CHE) as percentage of GDP Dataset WHO T1 Official 2 Oct 2026 GHED_CHEGDP_SHA2011: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"}; GHED_CHEGDP_SHA2011: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2022"}; GHED_CHEGDP_SHA2011: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2021"} 4540
WHO current health expenditure (CHE) per capita in US$ Dataset WHO T1 Official 2 Oct 2026 GHED_CHE_pc_US_SHA2011: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"}; GHED_CHE_pc_US_SHA2011: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2022"}; GHED_CHE_pc_US_SHA2011: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2021"} 4537
WHO/UNICEF DTP3 immunization coverage among 1-year-olds Dataset WHO T1 Official 2 Oct 2026 WHS4_100: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2025"}; WHS4_100: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2024"}; WHS4_100: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"} 4999
WHO domestic general government health expenditure as percentage of GDP Dataset WHO T1 Official 2 Oct 2026 GHED_GGHE-DGDP_SHA2011: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"}; GHED_GGHE-DGDP_SHA2011: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2022"}; GHED_GGHE-DGDP_SHA2011: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2021"} 4540
New strategy to build a healthier market for childhood cancer medicines Press release WHO T1 Official 16 Sep 2026 New strategy to build a healthier market for childhood cancer medicines; Note to the editor; Implementing the foundations of the strategy 6
WHO/UNICEF MCV1 immunization coverage among 1-year-olds Dataset WHO T1 Official 2 Oct 2026 WHS8_110: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2025"}; WHS8_110: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2024"}; WHS8_110: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"} 4999
WHO/UNICEF MCV2 immunization coverage by recommended age Dataset WHO T1 Official 2 Oct 2026 MCV2: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2025"}; MCV2: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2024"}; MCV2: {"SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"} 4999
WHO age-standardized NCD mortality rate (per 100,000 population, both sexes) Dataset WHO T1 Official 3 Oct 2026 WHS2_131: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2021"}; WHS2_131: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2020"}; WHS2_131: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2019"} 4070
WHO probability of premature death from four main NCDs (ages 30–70, %) Dataset WHO T1 Official 3 Oct 2026 NCDMORT3070: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2021"}; NCDMORT3070: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2020"}; NCDMORT3070: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2019"} 4070
Chile becomes first country in South America validated for eliminating dog-transmitted rabies as a public health problem Press release WHO T1 Official 16 Sep 2026 About rabies and neglected tropical diseases; About WHO 2
WHO age-standardized suicide mortality rate (per 100,000 population, both sexes) Dataset WHO T1 Official 3 Oct 2026 MH_12: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2021"}; MH_12: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2020"}; MH_12: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2019"} 4070
WHO tobacco use prevalence (ages 15+, age-standardized, both sexes) Dataset WHO T1 Official 2 Oct 2026 M_Est_tob_curr_std: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2024"}; M_Est_tob_curr_std: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"}; M_Est_tob_curr_std: {"Dim1":"SEX_BTSX","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2022"} 1494
WHO tobacco use prevalence (ages 15+, age-standardized, female) Dataset WHO T1 Official 2 Oct 2026 M_Est_tob_curr_std: {"Dim1":"SEX_FMLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2024"}; M_Est_tob_curr_std: {"Dim1":"SEX_FMLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"}; M_Est_tob_curr_std: {"Dim1":"SEX_FMLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2022"} 1494
WHO tobacco use prevalence (ages 15+, age-standardized, male) Dataset WHO T1 Official 2 Oct 2026 M_Est_tob_curr_std: {"Dim1":"SEX_MLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2024"}; M_Est_tob_curr_std: {"Dim1":"SEX_MLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2023"}; M_Est_tob_curr_std: {"Dim1":"SEX_MLE","SpatialDim":"AFG","SpatialDimType":"COUNTRY","TimeDim":"2022"} 1494
Supporting patients through research collaboration Press release IQVIA T3 Research 16 Sep 2026 Over the past 5 years patient organizations have received over 62.5 billion in revenue; Key findings:; Other findings 7
Strengthening Pathways for Cell and Gene Therapies: Current State and Future Scenarios Press release IQVIA T3 Research 15 Sep 2026 Cell and gene therapy clinical trial starts by type, 2013-2023; Key findings; Global cell and gene therapy spending and share by geography 11
Global R&D Trends 2026 Press release IQVIA T3 Research 15 Sep 2026 Exhibit 55: Country utilization as percentage of global trial country uses, 2019 and 2025; Exhibit 21: Small molecule share of trial starts by phase and company segment, 2016–2025; Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025 7
Rethinking Clinical Trial Country Prioritization Press release IQVIA T3 Research 15 Sep 2026 Key findings 2
U.S. Medicine Use Trends 2026 Press release IQVIA T3 Research 15 Sep 2026 Other Findings; Key Findings 14
Global Oncology Trends 2025 Press release IQVIA T3 Research 16 Sep 2026 Other Findings; Key Findings: Oncology R&D activity continues to grow driven by novel modalities; Key Findings: Oncology clinical development productivity has improved but remains challenging 27
Global Medicine Use Trends 2026 Press release IQVIA T3 Research 15 Sep 2026 Exhibit 4: Historical and projected per capita use of medicine by region, 2015–2030; Key Findings; Exhibit 20: High growth developed and Pharmerging markets spending and growth,constant US$, 2015–2030 5
Global R&D Trends 2026 Press release IQVIA T3 Research 15 Sep 2026 Exhibit 33: Novel active substances (NAS) launched globally and in selected countries, 2006–2025; Key Findings; Exhibit 18: Clinical trial starts by year and phase, 2016–2025 6

Report snapshots are retained internally for verification only and are never redistributed. Where a figure comes from a paywalled report, only the number published in its public summary is recorded.

Cite and reuse

Published under CC BY 4.0. Reuse is free, including commercially, with attribution.

StatOrigin. (2026). Healthcare Industry Statistics. Retrieved from https://statorigin.org/industries/healthcare

Download CSVExcel (.xlsx)JSONAPI docs

Found an error? Report it. We answer within 48 hours and log every correction on the corrections page.